

References

1. Balhara P, Jain A. A urinalysis-based study of buprenorphine and non-prescription opioid use among patients on buprenorphine maintenance. *Journal of Pharmacology and Therapeutics*. 2012, 1:15-19.
2. Bisaga A, Mannelli P, Yu M, Nangia N, Graham C, Tompkins D, Kosten T, Akerman S, Silverman B and Sullivan M. Outpatient transition to extended-release naltrexone for patients with opioid use disorder: A phase 3 randomized trial. *Drug and Alcohol Dependence*. 2018;187:171-78.
3. Hulse G. Subcutaneous naltrexone implants reduce opioid use in opiate dependent patients. *Evidence-Based Mental Health*. 2010;13:25.
4. Hulse G, Morris N, Arnold-Reed D, and Tait R. Improving clinical outcomes in treating heroin dependence: Randomized, controlled trial of oral or implant naltrexone. *Archives of General Psychiatry*. 2009;66:1108-15.
5. Lee J, Friedmann P, Kinlock T, Nune V, Boney T, Hoskinson, R and O'Brien C. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *New England Journal of Medicine*. 2016;374:1232–1242.
6. Mishlen K, Barbieri V, Sullivan M and Bisaga A. Opioid use following an outpatient detoxification and induction onto XR-NTX: Testing the blockade as a predictor of retention in treatment. *Drug and Alcohol Dependence*. 2017;171:e146.
7. Nielsen S, Hillhouse M, Weiss R, Mooney L, Sharpe J, Lee J, Gourevitch M and Ling W. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. *American Journal on Addictions*. 2014;23:343-8.
8. Nunes E, Gordon M, Friedmann P, Fishman M, Lee L, Chen D, Hu M, Boney T, Wilson D and O'Brien C. Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. *Journal of Substance Abuse Treatment*. 2018;85:49-55.
9. Solli k, Latif Z, Opheim A, Krajci P, Sharma-Haase K, Benth K, Tatum L and Kunoe N. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial. *Addiction*. 2018;113:1040-1849.
10. Tanum L, Solli K, Latif Z. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial. *JAMA Psychiatry*. 2017;74:1197-1205.

11. Weiss R, Potter J, Griffin M, Provost S, Fitzmaurice G, McDermott K and Carroll K. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Treatment Study. *Drug and Alcohol Dependence*. 2015;150:112-9.
12. Weiss R, Griffin M, Potter J, Dodd D, Dreifuss J, Connery H and Carroll K. Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management? *Drug and Alcohol Dependence*. 2014;140:118-22.
13. Williams A, Tofighi B, Rotrosen J, Lee J and Grossman E. Psychiatric comorbidity, red flag behaviors, and associated outcomes among office-based buprenorphine patients following hurricane Sandy. *Journal of Urban Health*. 2014;91:366-75.